Stockreport

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape [Seeking Alpha]

G1 Therapeutics, Inc.  (GTHX) 
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: g1therapeutics.com/pages/investors/investors.htm
PDF Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with Extensive-Stage Small Cell Lung Cancer. The company's re [Read more]